Elena Morariu is an Endocrinology/Metabolic physician affiliated with University of Pittsburgh Medical Center. OpenAlex indexes 29 publications with 313 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 5th Ave
Falk Clinic, Suite 2b
Pittsburgh, PA 152133403
Telephone
412-586-9700Registry record last updated 6 Apr 2021.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Xeris Pharmaceuticals, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
51.4%l-Thyroxine45.4%Levothyroxine Sodium70%Synthroid30%Part D≥114 patientsThyroid Hormone Synthesis Inhibitor4.7%Methimazole100%Part D≥18 patients+ 1 more class in this area
Metabolism & gastrointestinal
43%GLP-1 receptor agonist22.5%Ozempic36%Mounjaro30%Trulicity28%Rybelsus7%Part D<11 patientsInsulin Analog8.7%Lantus Solostar53%Humalog Kwikpen U-10034%Basaglar Kwikpen U-10013%Part D<11 patients+ 4 more classes in this area
Sensory organs
2.7%Corticosteroid2.7%Hydrocortisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 565 IGF2BP3-Overexpressing Thyroid Tumors are Morphologically and Immunophenotypically Distinct
Laboratory Investigation
2026 - Selective JAK1 inhibition remits multiorgan autoimmunity in a patient with refractory autoimmune polyendocrine syndrome type 1
Journal of Allergy and Clinical Immunology
2025 - IGF2BP3-Overexpressing Thyroid Tumors are Morphologically and Immunophenotypically Distinct
Zenodo (CERN European Organization for Nuclear Research)
2025 - IGF2BP3-Overexpressing Thyroid Tumors are Morphologically and Immunophenotypically Distinct
Zenodo (CERN European Organization for Nuclear Research)
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Mubashir Mumtaz, MD
University of Pittsburgh Medical Center
Chadi Hage, MD
University of Pittsburgh Medical Center
Matthew Schuchert
University of Pittsburgh Medical Center
Seungwon Kim
University of Pittsburgh Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”